Etodolac ext-rel Tablets Rx
Generic Name and Formulations:
Etodolac 400mg, 500mg, 600mg; ext rel tabs.
Various generic manufacturers
Indications for Etodolac ext-rel Tablets:
Osteoarthritis. Rheumatoid arthritis. Juvenile rheumatoid arthritis (JRA).
Use lowest effective dose for shortest duration. Initially 400–1000mg once daily.
<6yrs: not established. Use lowest effective dose for shortest duration. Give once daily. JRA: 6–16yrs (20–30kg): 400mg; (31–45kg): 600mg; (46–60kg): 800mg; (>60kg): 1000mg.
Aspirin allergy. Coronary artery bypass graft surgery.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Advanced renal disease: not recommended. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic and renal function in long-term therapy. Pre-existing asthma. Discontinue at 1st sign of rash or any other hypersensitivity. Renal or hepatic impairment. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C; 3rd trimester: avoid). Nursing mothers: not recommended.
NSAID (pyranocarboxylic acid deriv.).
Avoid concomitant aspirin, salicylates, phenylbutazone, or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors, ARBs, or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. May cause false (+) urinary bilirubin test.
GI upset, dizziness, headache, rash (may be severe), anemia, edema, pruritus, tinnitus; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypersensitivity reactions.
Formerly known under the brand names Lodine (caps, tabs); Lodine XL (ext-rel tabs).
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Weight Gain After Quitting Smoking May Increase Risk for T2D
- In Teens, Young Adults, High BMI May Hurt Cardiovascular Health
- Obesity Paradox Affects Type 2 Diabetes Mortality Rates
- Bi-Directional Association Observed Between Obstructive Sleep Apnea and Diabetes
- Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis